These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36216198)

  • 1. Inhibition on XBP1s-driven lipogenesis by Qushi Huayu Decoction contributes to amelioration of hepatic steatosis induced by fructose.
    Tian H; Fang Y; Liu W; Wang J; Zhao J; Tang H; Yin Y; Hu Y; Peng J
    J Ethnopharmacol; 2023 Jan; 301():115806. PubMed ID: 36216198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
    Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ
    Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte leukotriene B4 receptor 1 promotes NAFLD development in obesity.
    Liu X; Wang K; Wang L; Kong L; Hou S; Wan Y; Ma C; Chen J; Xing X; Xing C; Jiang Q; Zhao Q; Cui B; Huang Z; Li P
    Hepatology; 2023 Aug; 78(2):562-577. PubMed ID: 35931467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qushi Huayu Decoction Inhibits Hepatic Lipid Accumulation by Activating AMP-Activated Protein Kinase In Vivo and In Vitro.
    Feng Q; Gou XJ; Meng SX; Huang C; Zhang YQ; Tang YJ; Wang WJ; Xu L; Peng JH; Hu YY
    Evid Based Complement Alternat Med; 2013; 2013():184358. PubMed ID: 23573117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Qushi Huayu decoction attenuated hepatic lipid accumulation via JAK2/STAT3/CPT-1A-related fatty acid β-oxidation in mice with non-alcoholic steatohepatitis.
    Sun Q; Wang X; Xin X; An Z; Hu Y; Feng Q
    Pharm Biol; 2022 Dec; 60(1):2124-2133. PubMed ID: 36308318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amelioration of non-alcoholic steatohepatitis by Qushi Huayu decoction is associated with inhibition of the intestinal mitogen-activated protein kinase pathway.
    Leng J; Huang F; Hai Y; Tian H; Liu W; Fang Y; Hu Y; Peng J
    Phytomedicine; 2020 Jan; 66():153135. PubMed ID: 31790895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qushi Huayu decoction ameliorates non-alcoholic fatty liver disease in rats by modulating gut microbiota and serum lipids.
    Ni Y; Wang X; Wu Q; Yao Y; Xu Y; Li Y; Feng Q; Zhou M; Gou X
    Front Endocrinol (Lausanne); 2023; 14():1272214. PubMed ID: 37900123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic glucokinase regulatory protein and carbohydrate response element binding protein attenuation reduce de novo lipogenesis but do not mitigate intrahepatic triglyceride accumulation in Aldob deficiency.
    Buziau AM; Oosterveer MH; Wouters K; Bos T; Tolan DR; Agius L; Ford BE; Cassiman D; Stehouwer CDA; Schalkwijk CG; Brouwers MCGJ
    Mol Metab; 2024 Sep; 87():101984. PubMed ID: 38972375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.
    Softic S; Cohen DE; Kahn CR
    Dig Dis Sci; 2016 May; 61(5):1282-93. PubMed ID: 26856717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-targeting therapeutic mechanisms of the Chinese herbal medicine QHD in the treatment of non-alcoholic fatty liver disease.
    Feng Q; Liu W; Baker SS; Li H; Chen C; Liu Q; Tang S; Guan L; Tsompana M; Kozielski R; Baker RD; Peng J; Liu P; Zhu R; Hu Y; Zhu L
    Oncotarget; 2017 Apr; 8(17):27820-27838. PubMed ID: 28416740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with myo-inositol attenuates binding of the carbohydrate-responsive element-binding protein to the ChREBP-β and FASN genes in rat nonalcoholic fatty liver induced by high-fructose diet.
    Shimada M; Ichigo Y; Shirouchi B; Takashima S; Inagaki M; Nakagawa T; Hayakawa T
    Nutr Res; 2019 Apr; 64():49-55. PubMed ID: 30802722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing.
    Zeng H; Qin H; Liao M; Zheng E; Luo X; Xiao A; Li Y; Chen L; Wei L; Zhao L; Ruan XZ; Yang P; Chen Y
    Mol Metab; 2022 Mar; 57():101428. PubMed ID: 34974159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The chloroform extract of Cyclocarya paliurus attenuates high-fat diet induced non-alcoholic hepatic steatosis in Sprague Dawley rats.
    Lin Z; Wu ZF; Jiang CH; Zhang QW; Ouyang S; Che CT; Zhang J; Yin ZQ
    Phytomedicine; 2016 Nov; 23(12):1475-1483. PubMed ID: 27765368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of X-Box Binding Protein-1 in Fructose-Induced
    Yu X; Ren LP; Wang C; Zhu YJ; Xing HY; Zhao J; Song GY
    Chin Med J (Engl); 2018 Oct; 131(19):2310-2319. PubMed ID: 30246717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of adiponectin and adiponectin receptor 2 in the pathology of fatty liver].
    Li HS; Feng Q; Hu YY; Chen SD; Peng JH; Li XM; Xu LL
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):826-30. PubMed ID: 19958641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naringin attenuates fructose-induced NAFLD progression in rats through reducing endogenous triglyceride synthesis and activating the Nrf2/HO-1 pathway.
    Pengnet S; Sumarithum P; Phongnu N; Prommaouan S; Kantip N; Phoungpetchara I; Malakul W
    Front Pharmacol; 2022; 13():1049818. PubMed ID: 36588703
    [No Abstract]   [Full Text] [Related]  

  • 17. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effects of Long-Term High Fat and/or High Sugar Feeding on Sources of Postprandial Hepatic Glycogen and Triglyceride Synthesis in Mice.
    Reis-Costa A; Belew GD; Viegas I; Tavares LC; Meneses MJ; Patrício B; Gastaldelli A; Macedo MP; Jones JG
    Nutrients; 2024 Jul; 16(14):. PubMed ID: 39064628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials.
    Beysen C; Schroeder P; Wu E; Brevard J; Ribadeneira M; Lu W; Dole K; O'Reilly T; Morrow L; Hompesch M; Hellerstein MK; Li K; Johansson L; Kelly PF
    Diabetes Obes Metab; 2021 Mar; 23(3):700-710. PubMed ID: 33289350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease.
    Ter Horst KW; Serlie MJ
    Nutrients; 2017 Sep; 9(9):. PubMed ID: 28878197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.